Biomarkers and surrogate end points--the challenge of statistical validation.
about
Electrochemical, Electrochemiluminescence, and Photoelectrochemical Aptamer-Based Nanostructured Sensors for Biomarker AnalysisBiomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewConfirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceUpdating the OMERACT filter: implications for imaging and soluble biomarkersPro: 'The usefulness of biomarkers in glomerular diseases'. The problem: moving from syndrome to mechanism--individual patient variability in disease presentation, course and response to therapyConcordance of effects of medical interventions on hospital admission and readmission rates with effects on mortality204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The NetherlandsAdvancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational SummitQuality of Documentation as a Surrogate Marker for Awareness and Training Effectiveness of PHTLS-Courses. Part of the Prospective Longitudinal Mixed-Methods EPPTC-TrialImaging biomarker roadmap for cancer studiesTime-dependent endpoints as predictors of overall survival in multiple myelomaBiomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Markers for nutrition studies: review of criteria for the evaluation of markers.Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine.An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.Methods and challenges in quantitative imaging biomarker developmentPerinatal factors and regional brain volume abnormalities at term in a cohort of extremely low birth weight infantsProspective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabRare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.How close are we to customizing chemotherapy in early non-small cell lung cancer?Key concepts of clinical trials: a narrative reviewLymph node harvest in colon and rectal cancer: Current considerationsThe ARCAD clinical trials program: an update and invitation.Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.Biomarker development in the context of urologic cancersBiomarkers and surrogate endpoints in glaucoma clinical trials.Variation in Hospital-Specific Rates of Suboptimal Lymphadenectomy and Survival in Colon Cancer: Evidence from the National Cancer Data Base.Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.Promise and pitfalls of quantitative imaging in oncology clinical trials.Personalized medicine in breast cancer: a systematic review.Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicineChemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.Methodological assessment of HCC literatureImpact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology.Biomarker in Colorectal Cancer.A review of phase II trial designs for initial marker validation.Predictive value of initial triage vital signs for critically ill older adults
P2860
Q26739039-9BD79863-B72E-41FD-9727-FC38E8B54A01Q26766584-21C06143-06A3-41F3-956B-79355AF3C61AQ26782138-412C058C-5B70-445D-A5B9-985A34DD30E9Q27014889-53012054-E288-4A4A-97A9-5CEBFBDE1EA6Q27015909-68683743-1289-49F4-BB8A-EBBB7AAE8CEBQ27022171-F9ECDE47-4310-43FF-9705-2CCC22F4CF74Q28611318-1DE4DDBC-EDDE-4687-8163-73011C16604DQ28709591-F108EA13-8734-46A9-910B-1B8F0F0FDC83Q30151456-969E0AA7-A607-4C52-8958-4653D8A84885Q30242020-7712089E-BA70-4367-A8F3-CEDBD0718CD4Q30538040-C3612209-F869-4721-BBA0-029CB06911C7Q33756518-896D795C-0618-4651-A3E1-DB781A2BD86BQ34173001-0F0EA96D-979D-4F97-BFBC-DD083C2D7044Q34364879-85121ACA-51AD-4F50-AC0A-195353C0985FQ34535243-D0A40199-BA51-4915-9D03-739E56A61917Q34623196-5EBD63EF-665F-4E7F-AAA0-0A0FBAD44C9EQ34623884-5E1271BA-DBFB-4DF1-882F-2F05BF99075BQ34648114-D937CF92-C25E-4A84-99F1-5AEA5794F387Q34720825-BA3B27A2-79ED-41BA-B86D-328EC7465A20Q34825323-2B0A12F9-107F-47ED-9BD3-7933C655CB0BQ35005736-A54C84BA-8947-4E94-91A2-74B77BBB2C66Q35146944-8F7776EC-E2EC-435A-9DEF-C3CDFBE30208Q35738793-0989BC36-8191-4A0D-9218-2F54C5B79F0EQ35752056-8A0B48CE-2849-4B4C-B3EF-FABD5740E4E1Q35776224-74A49F7F-49BC-4D21-BFB3-28374073F424Q35874030-5370A0AD-AD2F-4F8B-B006-DF27AF4C4EDBQ35906352-375481FE-68DF-4317-AB93-17D426C3DED8Q35912696-1CF0DFB7-6C62-446D-BAB6-794C6E77743DQ36129165-20F29CA9-1BC6-43DD-ADA6-1403BA2AA0E9Q36243296-BF7B8EA6-FE12-404F-BF91-BFD201859027Q36303765-5E1951FB-F145-48D4-A366-AA9C8A472DB5Q36310182-0720DE37-FF49-4CB4-81A6-4C18B25B03B0Q36689052-ACE9FB4C-4542-48B5-9ADD-557A037DBE7FQ36690546-5807DAFF-49B7-47F2-86DC-B3FA1F8A5847Q36957747-D6B35E06-D3A3-48E2-A08A-E268365D4883Q36963820-1E93392A-3AD4-4109-863E-E82508C1A21FQ37100056-561A93AF-3EA1-4231-88DC-D06A2DBAAAB3Q37114675-519557E7-0720-4933-A233-33CB24265572Q37188715-67F5E7E2-B6B2-413C-A8E6-5A9B163510B4Q37213659-A111F1B0-1DE3-4381-A6C3-0E14D9482F19
P2860
Biomarkers and surrogate end points--the challenge of statistical validation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarkers and surrogate end points--the challenge of statistical validation.
@en
Biomarkers and surrogate end points--the challenge of statistical validation.
@nl
type
label
Biomarkers and surrogate end points--the challenge of statistical validation.
@en
Biomarkers and surrogate end points--the challenge of statistical validation.
@nl
prefLabel
Biomarkers and surrogate end points--the challenge of statistical validation.
@en
Biomarkers and surrogate end points--the challenge of statistical validation.
@nl
P2093
P1476
Biomarkers and surrogate end points--the challenge of statistical validation.
@en
P2093
Alastair Matheson
Axel Grothey
Daniel J Sargent
P304
P356
10.1038/NRCLINONC.2010.43
P407
P577
2010-04-06T00:00:00Z